Skip to main content
. 2016 Jan 22;10(5):516–524. doi: 10.1093/ecco-jcc/jjw008

Figure 2.

Figure 2.

Panel A: Cumulative probability of starting an immunomodulator from time of anti- tumour necrosis factor [TNF] monotherapy initiation in the overall population [n = 350]. Panel B: Cumulative probability of remaining on combination therapy from time of immunomodulator initiation in the 53 patients.